{"id":"https://openalex.org/W1948601338","doi":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","title":"Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review","display_name":"Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review","alternate_titles":[],"publication_year":2010,"publication_date":"2010-11-10","ids":{"openalex":"https://openalex.org/W1948601338","doi":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","mag":"1948601338","pmid":"https://pubmed.ncbi.nlm.nih.gov/21070215"},"language":"en","primary_location":{"id":"doi:10.1111/j.1528-1167.2010.02772.x","doi":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","pdf_url":null,"source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1948601338"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089343835","display_name":"Melissa Maguire","orcid":"https://orcid.org/0000-0002-5351-6743","observed_orcids":["https://orcid.org/0000-0002-5351-6743"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Melissa J. Maguire","raw_affiliation_strings":["Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom. Maguirem@doctors.org.uk","Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom. Maguirem@doctors.org.uk","institution_ids":["https://openalex.org/I146655781"]},{"raw_affiliation_string":"Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034023807","display_name":"Karla Hemming","orcid":"https://orcid.org/0000-0002-2226-6550","observed_orcids":["https://orcid.org/0000-0002-2226-6550"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karla Hemming","raw_affiliation_strings":["Department of Public Health, University of Birmingham, Birmingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Public Health, University of Birmingham, Birmingham, United Kingdom","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024606893","display_name":"John M. Wild","orcid":"https://orcid.org/0000-0003-3019-3889","observed_orcids":["https://orcid.org/0000-0003-3019-3889"]},"institutions":[{"id":"https://openalex.org/I79510175","display_name":"Cardiff University","ror":"https://ror.org/03kk7td41","country_code":"GB","type":"education","lineage":["https://openalex.org/I79510175"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"John M. Wild","raw_affiliation_strings":["Cardiff School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardiff School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom","institution_ids":["https://openalex.org/I79510175"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081969377","display_name":"Jane L. Hutton","orcid":"https://orcid.org/0000-0003-0963-9997","observed_orcids":["https://orcid.org/0000-0003-0963-9997"]},"institutions":[{"id":"https://openalex.org/I39555362","display_name":"University of Warwick","ror":"https://ror.org/01a77tt86","country_code":"GB","type":"education","lineage":["https://openalex.org/I39555362"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jane L. Hutton","raw_affiliation_strings":["Department of Statistics, University of Warwick, Coventry, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Statistics, University of Warwick, Coventry, United Kingdom","institution_ids":["https://openalex.org/I39555362"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005069325","display_name":"Anthony Guy Marson","orcid":"https://orcid.org/0000-0002-6861-8806","observed_orcids":["https://orcid.org/0000-0002-6861-8806"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anthony G. Marson","raw_affiliation_strings":["Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurological Science, University of Liverpool, Liverpool, United Kingdom","institution_ids":["https://openalex.org/I146655781"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5089343835"],"corresponding_institution_ids":["https://openalex.org/I146655781"],"apc_list":{"value":4360,"currency":"USD","value_usd":4360},"apc_paid":null,"fwci":2.2552,"has_fulltext":false,"cited_by_count":168,"citation_normalized_percentile":{"value":0.8994709,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"51","issue":"12","first_page":"2423","last_page":"2431"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.6977999806404114,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.6977999806404114,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.25589999556541443,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.0364999994635582,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vigabatrin","display_name":"vigabatrin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/visual-field-defects","display_name":"visual field defects","score":0.9829999804496765},{"id":"https://openalex.org/keywords/focal-epilepsy","display_name":"focal epilepsy","score":0.6819999814033508},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.8130000233650208},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.7450000047683716},{"id":"https://openalex.org/keywords/prevalence","display_name":"prevalence","score":0.4410000145435333},{"id":"https://openalex.org/keywords/risk-factors","display_name":"risk factors","score":0.8119999766349792},{"id":"https://openalex.org/keywords/cumulative-dose","display_name":"cumulative dose","score":0.8180000185966492},{"id":"https://openalex.org/keywords/age","display_name":"age","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C2780837902","wikidata":"https://www.wikidata.org/wiki/Q421663","display_name":"Vigabatrin","level":4,"score":0.9833704233169556},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7070018649101257},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.651704728603363},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.5917130708694458},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5749115347862244},{"id":"https://openalex.org/C2776058522","wikidata":"https://www.wikidata.org/wiki/Q2364768","display_name":"Visual field","level":2,"score":0.5458285808563232},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.5395926237106323},{"id":"https://openalex.org/C2908575184","wikidata":"https://www.wikidata.org/wiki/Q2364768","display_name":"Visual field loss","level":3,"score":0.5038771033287048},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.4125780165195465},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.21806856989860535},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19171971082687378},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.13768669962882996},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.12765318155288696}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004828","descriptor_name":"Epilepsies, Partial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014786","descriptor_name":"Vision Disorders","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D014786","descriptor_name":"Vision Disorders","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D014786","descriptor_name":"Vision Disorders","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014794","descriptor_name":"Visual Fields","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D015995","descriptor_name":"Prevalence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020888","descriptor_name":"Vigabatrin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D020888","descriptor_name":"Vigabatrin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058609","descriptor_name":"Visual Field Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/j.1528-1167.2010.02772.x","doi":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1528-1167.2010.02772.x","pdf_url":null,"source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},{"id":"pmid:21070215","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21070215","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"Comparative Study"},{"id":"pmh:oai:https://orca.cardiff.ac.uk:43826","doi":null,"is_oa":false,"landing_page_url":"https://orca.cardiff.ac.uk/id/eprint/43826/","pdf_url":null,"source":{"id":"https://openalex.org/S4306401195","display_name":"ORCA Online Research @Cardiff (Cardiff University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79510175","host_organization_name":"Cardiff University","host_organization_lineage":["https://openalex.org/I79510175"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/ef4096fe-4d12-4da0-8ccb-c72b05b88ad4","doi":null,"is_oa":false,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/ef4096fe-4d12-4da0-8ccb-c72b05b88ad4","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Maguire, MJ, Hemming, K, Wild, JM, Hutton, JL & Marson, AG 2010, 'Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review.', Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02772.x","raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":60,"referenced_works":["https://openalex.org/W129673096","https://openalex.org/W206834145","https://openalex.org/W1479962834","https://openalex.org/W1604045591","https://openalex.org/W1607402462","https://openalex.org/W1864558401","https://openalex.org/W1963519141","https://openalex.org/W1964151041","https://openalex.org/W1985422482","https://openalex.org/W1988302543","https://openalex.org/W1997212410","https://openalex.org/W2000723957","https://openalex.org/W2000997080","https://openalex.org/W2002141786","https://openalex.org/W2004131639","https://openalex.org/W2005689818","https://openalex.org/W2012124964","https://openalex.org/W2016655873","https://openalex.org/W2020270040","https://openalex.org/W2021547803","https://openalex.org/W2027002046","https://openalex.org/W2038749218","https://openalex.org/W2042103292","https://openalex.org/W2043559003","https://openalex.org/W2049214932","https://openalex.org/W2050219242","https://openalex.org/W2064531305","https://openalex.org/W2070403944","https://openalex.org/W2077904600","https://openalex.org/W2080221650","https://openalex.org/W2085048192","https://openalex.org/W2085050047","https://openalex.org/W2085708319","https://openalex.org/W2088030006","https://openalex.org/W2088132894","https://openalex.org/W2090232489","https://openalex.org/W2095185628","https://openalex.org/W2099979442","https://openalex.org/W2102800930","https://openalex.org/W2114390763","https://openalex.org/W2116602570","https://openalex.org/W2131913382","https://openalex.org/W2138475110","https://openalex.org/W2149094349","https://openalex.org/W2157823046","https://openalex.org/W2157888408","https://openalex.org/W2162594619","https://openalex.org/W2164834633","https://openalex.org/W2171386011","https://openalex.org/W2250117813","https://openalex.org/W2294804959","https://openalex.org/W2319153251","https://openalex.org/W2340191118","https://openalex.org/W2394691376","https://openalex.org/W2410164853","https://openalex.org/W2436674713","https://openalex.org/W2440855764","https://openalex.org/W4238087098","https://openalex.org/W4246029029","https://openalex.org/W4247243686"],"related_works":["https://openalex.org/W1607402462","https://openalex.org/W2069565378","https://openalex.org/W1974267703","https://openalex.org/W2014407178","https://openalex.org/W2088030006","https://openalex.org/W2138475110","https://openalex.org/W2283219775","https://openalex.org/W1604045591","https://openalex.org/W2158155037","https://openalex.org/W2406939288"],"abstract_inverted_index":{"PURPOSE:":[0],"Vigabatrin":[1,219],"is":[2,230],"an":[3],"efficacious":[4],"antiepileptic":[5],"drug":[6],"licensed":[7],"as":[8],"add-on":[9],"therapy":[10],"in":[11,16,74,86,189],"refractory":[12],"epilepsy":[13,90,226],"and":[14,27,53,67,104,130,203],"used":[15],"infantile":[17],"spasms.":[18],"Eight":[19],"years":[20],"after":[21],"licensing,":[22],"there":[23,229],"emerged":[24],"a":[25,38,209],"strong":[26],"possibly":[28],"causative":[29],"association":[30],"with":[31,88,92,100,115,161,208,214,225],"bilateral":[32],"visual":[33,49,83,101,141,162,215],"field":[34,50,84,102,142,163,187,216],"loss.":[35,217],"We":[36],"report":[37],"systematic":[39],"review":[40],"ascertaining":[41],"the":[42,80,98,105,134,150,157,240,247],"magnitude":[43],"of":[44,46,57,76,82,108,159,201,212,242,249],"risk":[45,107,185,248],"vigabatrin":[47,93,129,202],"associated":[48,207],"loss":[51,85,143,164,188],"(VAVFL)":[52],"any":[54],"clinical":[55],"predictors":[56],"risk.":[58],"METHODS:":[59],"Electronic":[60],"searches,":[61],"including":[62],"MEDLINE":[63],"(1966-2009),":[64],"EMBASE":[65],"(1974-2009),":[66],"CINAHL":[68],"(1982-2009),":[69],"were":[70,94,97,121,206],"conducted.":[71],"Reports,":[72],"published":[73],"full,":[75],"observational":[77],"studies":[78,120],"investigating":[79],"prevalence":[81],"patients":[87,114,126,191,213,224,236],"partial":[89],"treated":[91],"included.":[95],"Outcomes":[96],"proportion":[99,158,211],"loss,":[103],"relative":[106,184],"VAVFL":[109],"compared":[110,144],"to":[111,128,145,245],"similar":[112],"nonexposed":[113],"epilepsy.":[116],"KEY":[117],"FINDINGS:":[118],"Thirty-two":[119],"identified,":[122],"which":[123],"included":[124],"1,678":[125,135],"exposed":[127,136],"406":[131,151],"controls.":[132,152],"Of":[133],"patients,":[137],"738":[138],"(44%)":[139],"had":[140],"just":[146],"30":[147],"(7%)":[148],"among":[149],"The":[153,172,183],"random-effects":[154],"estimate":[155,173],"for":[156,174,186,223,227,235],"adults":[160],"was":[165,176,192],"52%":[166],"[95%":[167],"confidence":[168],"interval":[169],"(CI)":[170],"46-59].":[171],"children":[175],"lower":[177],"at":[178],"34%":[179],"(95%":[180,194],"CI":[181,195],"25-42).":[182],"vigabatrin-exposed":[190],"4.0":[193],"2.9-5.5).":[196],"Larger":[197],"mean":[198],"cumulative":[199],"dose":[200],"increasing":[204],"age":[205],"higher":[210],"SIGNIFICANCE:":[218],"should":[220],"be":[221],"reserved":[222],"whom":[228],"no":[231],"other":[232],"alternative":[233],"or":[234],"who":[237],"have":[238],"determined":[239],"benefit":[241],"ongoing":[243],"treatment":[244],"outweigh":[246],"VAVFL.":[250]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1948601338","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":16},{"year":2012,"cited_by_count":17}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
